Incyte Corp. Common Stock (INCY)
Stock · NASDAQ · Health Care
$113.12as of 10/16/2026
Price chart
Active signals
INCY Signal Track Record
How signals performed across all stocks →What INCY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | +0.5% | 56% | September 18, 2026 |
| Bollinger Band Breakout | 23 | +1.6% | 61% | July 28, 2026 |
| 200-Day Moving Average TouchActive now | 22 | -0.5% | 45% | June 1, 2026 |
| Bollinger Band Breakdown | 18 | -2.6% | 39% | October 1, 2026 |
| Any 20-session window (baseline) | +0.8% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acut…
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Employees
- 2,844
- Website
- www.incyte.com/
Fundamentals
- 1-day range
- $112.02$114.56
- Market cap
- $24.00B
- P/E (trailing)
- 14.30
- P/E (forward)
- 13.03
- EPS (trailing)
- $7.85
- Dividend yield
- —
- Beta
- 0.78
- Avg. volume
- 1.65M
How Incyte Corp. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 10, 2026 · via SEC EDGAR / Finnhub
Forecasts
24 analyst ratings
Incyte Corp. Common Stock Competitors
Chosen by industry and closest market cap.
- INCYIncyte Corp. Common Stock$113.07▼ 0.18%Market cap $24.00BP/E 14.30$84.02$132.6
- MEDPMedpace Holdings Inc. Common Stock$618.47▼ 1.61%Market cap $16.33BP/E 35.88$373$677.9
- CRLCharles River Laboratories International Inc. Common Stock$300.15▼ 1.99%Market cap $12.79BP/E —$146.2$333.3
- ICLRICON plc Ordinary Shares$170.18▼ 2.83%Market cap $12.34BP/E 190.41$66.57$203.91
- IQVIQVIA Holdings Inc. Common Stock$266.9▼ 1.53%Market cap $38.26BP/E 32.32$154.5$277.4
- ABSIAbsci Corporation Common Stock$8.25▼ 7.09%Market cap $1.29BP/E —$2.24$12.06
- NRCNRC Health Common Stock$20.15▼ 4.55%Market cap $430.67MP/E 79.70$11.01$23.68
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| INCY Incyte Corp. Common Stock | $24.00B | 14.30 | $113.07 | ▼ 0.18% | $84.02$132.6 |
| MEDP Medpace Holdings Inc. Common Stock | $16.33B | 35.88 | $618.47 | ▼ 1.61% | $373$677.9 |
| CRL Charles River Laboratories International Inc. Common Stock | $12.79B | — | $300.15 | ▼ 1.99% | $146.2$333.3 |
| ICLR ICON plc Ordinary Shares | $12.34B | 190.41 | $170.18 | ▼ 2.83% | $66.57$203.91 |
| IQV IQVIA Holdings Inc. Common Stock | $38.26B | 32.32 | $266.9 | ▼ 1.53% | $154.5$277.4 |
| ABSI Absci Corporation Common Stock | $1.29B | — | $8.25 | ▼ 7.09% | $2.24$12.06 |
| NRC NRC Health Common Stock | $430.67M | 79.70 | $20.15 | ▼ 4.55% | $11.01$23.68 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Why Is Arcutis Biotherapeutics Stock Surging Thursday?benzinga · 10/15/2026
- Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology SegmentYahoo · 10/1/2026
- If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much TodayBenzinga · 10/1/2026
- Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $128Benzinga · 10/1/2026
- INCY or TECH: Which Is the Better Value Stock Right Now?Yahoo · 9/30/2026
- Incyte (NASDAQ:INCY) Combines High Growth Momentum With a Breakout SetupChartMill · 9/30/2026
- MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder TherapyYahoo · 9/28/2026
- LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair LossYahoo · 9/28/2026
- JP Morgan Maintains Neutral on Incyte, Raises Price Target to $123Benzinga · 9/28/2026
Insider Activity
Insider Actions →- Paul J. Clancy · September 30, 2026 · Grant203 @ $121.35
- Edmund Harrigan · September 30, 2026 · Grant206 @ $121.35
- BAKER BROS. ADVISORS LP · September 30, 2026 · Grant322
- David H. Gardner · September 22, 2026 · Tax Withholding920 @ $126.93
- Pablo J. Cagnoni · September 15, 2026 · Option Exercise9.2K @ $71.93
- Pablo J. Cagnoni · September 15, 2026 · Option Exercise6.5K @ $64.25
- Pablo J. Cagnoni · September 15, 2026 · Option Exercise4.6K @ $61.18
- Pablo J. Cagnoni · September 15, 2026 · Option Exercise3.0K @ $61.76
- Pablo J. Cagnoni · September 15, 2026 · Sale14.0K @ $120.49
- Pablo J. Cagnoni · September 15, 2026 · Sale9.2K @ $120.5
- Ramitpal K. Basi · August 25, 2026 · Tax Withholding504 @ $129.72
- Pablo J. Cagnoni · August 19, 2026 · Sale10.8K @ $125.56
- Pablo J. Cagnoni · August 12, 2026 · Sale10.8K @ $120.04
- Patrick A. Mayes · August 5, 2026 · Option Exercise2.2K @ $106.47
- Patrick A. Mayes · August 5, 2026 · Sale2.2K @ $123.99
Institutional Ownership
March 31, 2026
- Total shares held
- 192.63M
- Total value held
- $17.30B
- Institutional holders
- 800
- Unknown30.74M
- Unknown18.98M
- Unknown12.25M
- Unknown10.93M
- Unknown9.64M
- Unknown5.81M
- Unknown4.70M
- Unknown3.92M
- Unknown3.87M
- Unknown3.65M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Incyte receives mixed analyst updates with price target changes
Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.
Incyte receives mixed analyst updates with price target changes. Incyte saw two recent analyst actions with differing views. Truist Securities raised its price target to $115 while maintaining a Hold rating. Conversely, HC Wainwright reiterated a Buy rating and kept its target at $152. These moves reflect a wide range of expectations among analysts for the stock's future performance.